1 |
Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome[J]. Nephrol Dial Transplant,2008,23(6):1919-1925.
|
2 |
Li H, Shi X, Shen H, et al. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label,nonrandomized cohort trial [J]. Clin Ther,2012,34(5):1112-1120.
|
3 |
Kidney Disease: Improving Global Outcomes ( KDIGO )Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Int Suppl, 2012, 2(2): 139-174.
|
4 |
He L, Peng Y, Liu H, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids [J]. J Nephrol,2013,26(3):564-571.
|
5 |
Xie G, Xu J, Ye C, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults [J]. PLoS One,2012,7(9): e44330.
|
6 |
Praga M, Barrio V, Juárez GF, et al. Tacrolimus monotherapy in membranous nephropathy:a randomized controlled trial[J]. Kidney Int,2007,71(9):924-930.
|
7 |
Chen W, Liu Q, Liao Y, et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial [J]. Am J Med Sci, 2013,345(2):81-87.
|
8 |
Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy[J]. Nephrol Dial Transplant,2004,19(12):3062-3067.
|
9 |
Ren H,Shen P,Li X,et al. Tacrolimus versus cyclophosphamide in steroid-dependentorsteroid-resistantfocalsegmental glomerulosclerosis: a randomized controlled trial [ J]. Am J Nephrol,2013,37(1):84-90.
|
10 |
Segarra A,Vila J,Pou L,et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up [J]. Nephrol Dial Transplant,2002,17(4):655-662.
|
11 |
Zhang Q,Shi SF, Zhu L,et al. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy [J]. Am J Nephrol,2012,35(4):312-320.
|
12 |
Wang S, Li X, Qu L, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study [J]. Lupus, 2012, 21(9):1025-1035.
|
13 |
Deng J, Huo D, Wu Q, et al. A meta-analysis of randomized controlledtrialscomparingtacrolimuswithintravenous cyclophosphamide in the induction treatment for lupus nephritis[J].Tohoku J Exp Med,2012,227(4):281-288.
|
14 |
Fei Y, Wu Q, Zhang W, et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study [J]. Clin Exp Rheumatol,2013,31(1):62-68.
|
15 |
Bhimma R, Adhikari M, Asharam K, et al. Management of steroidresistant focal segmental glomerulosclerosis in children using tacrolimus [J]. Am J Nephrol,2006,26(6):544-551.
|
16 |
Yang M, Li M, He W, et al. Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis[J]. Exp Ther Med,2014,7(6):1663-1670.
|
17 |
Gordon S, Denunzio T, Uy A. Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria [J]. Hawaii J Med Public Health, 2013, 72(9 Suppl 4):18-23.
|
18 |
Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus, 2013, 22(11):1135-1141.
|
19 |
Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome:a randomized controlled trial[J]. Am J Kidney Dis,2009,53(5):760-769.
|